Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. (NYSE: RCUS) generates frequent news as a clinical-stage, global biopharmaceutical company advancing investigational therapies for cancer, inflammatory diseases and autoimmune diseases. News about Arcus often centers on clinical trial updates for its lead programs, collaboration developments and corporate financing activities that support its pipeline.
Key oncology news items include data readouts and study milestones for casdatifan, a small-molecule HIF‑2α inhibitor being developed for clear cell renal cell carcinoma (ccRCC). Investors can follow announcements from the ARC‑20 Phase 1/1b study in late-line and early-line ccRCC, the global Phase 3 PEAK‑1 trial in immunotherapy-experienced metastatic ccRCC, and the eVOLVE‑RCC02 Phase 1b/3 study that combines casdatifan with volrustomig in first-line metastatic ccRCC. Updates often highlight progression-free survival, response rates, safety findings and the design of new cohorts or registrational strategies.
Arcus news also covers its broader oncology portfolio, including quemliclustat, a CD73 inhibitor in the PRISM‑1 Phase 3 trial for first-line metastatic pancreatic ductal adenocarcinoma, and the domvanalimab plus zimberelimab combinations in gastrointestinal and lung cancers. Coverage has included positive survival and response data from the Phase 2 EDGE‑Gastric study, as well as the later decision to discontinue the Phase 3 STAR‑221 and EDGE‑Gastric studies after an interim analysis showed no overall survival benefit over standard therapy.
On the inflammation and immunology side, Arcus issues updates on its emerging small-molecule programs targeting MRGPRX2, TNF, CCR6 and CD40L, and an anti‑CD89 antibody program. News may describe preclinical progress, selection of development candidates and plans to enter the clinic in indications such as atopic dermatitis, chronic spontaneous urticaria, rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis and systemic lupus erythematosus.
Corporate and financial news for RCUS includes public equity offerings, amendments to loan facilities, participation in major healthcare and investor conferences, and guidance on cash runway. Readers can use this news page to follow how clinical data, partnership decisions with Gilead Sciences and Taiho Pharmaceutical, and capital-raising activities shape Arcus’s development priorities over time.
Arcus Biosciences (NYSE:RCUS) announced inducement equity awards for two new hires on March 24, 2026. The Compensation Committee granted options to purchase 7,050 shares at an exercise price of $21.41 (March 23, 2026 close) and 3,550 restricted stock units.
The awards were made under the company’s 2020 Inducement Plan pursuant to the NYSE Listed Company Manual Rule 303A.08 inducement exception.
Arcus Biosciences (NYSE:RCUS) announced inducement equity awards for two new employees on March 9, 2026. The Compensation Committee granted options to purchase 17,050 shares at an exercise price of $23.43 per share and 8,550 restricted stock units under the company’s 2020 Inducement Plan. The awards used the NYSE "inducement exception" (Rule 303A.08) and reflect hiring-related equity compensation for clinical-stage operations.
Arcus Biosciences (NYSE:RCUS) said its management team will participate in two investor conferences in Miami in March 2026: the Leerink Global Healthcare Conference on March 9 (fireside chat & 1x1s) and the Barclays 28th Annual Global Healthcare Conference on March 10 (1x1s).
A live webcast of the March 9 fireside chat will be available via the company’s Investors & Media website, with a replay posted after the event.
Arcus Biosciences (NYSE:RCUS) reported Q4 and full-year 2025 results and a pipeline update highlighting clinical progress for casdatifan and balance sheet strength. Casdatifan 100mg QD showed median PFS of 15.1 months and confirmed ORR of 45.2% (DCO Jan 30, 2026).
PEAK-1 Phase 3 is enrolling; a 1L registrational Phase 3 is planned by end-2026. Cash totaled $1.0 billion at year-end, supporting runway into at least H2 2028. Quemliclustat Phase 3 enrollment completed; results expected H1 2027.
Arcus Biosciences (NYSE:RCUS) reported updated ARC-20 results for casdatifan in late-line metastatic clear cell RCC. The 100mg QD tablet cohort showed mPFS 15.1 months and cORR 45% (DCO Jan 30, 2026). Pooled mPFS was 12.2 months with cORR 35%. Biomarker analysis linked sustained sEPO suppression to clinical benefit. No unexpected safety signals were observed; anemia-related discontinuations were 0% and hypoxia discontinuations were 3%.
Arcus Biosciences (NYSE:RCUS) will host a conference call and webcast on Feb 25, 2026 at 1:30 PM PT / 4:30 PM ET to discuss fourth-quarter and full-year 2025 financial results and a pipeline update.
Investors can join by phone (Access Code: 190500), register online, or view a live webcast and slide presentation on the company website; a replay will be available after the event.
Arcus Biosciences (NYSE:RCUS) announced inducement equity awards for three new employees under its 2020 Inducement Plan. The Compensation Committee granted options to purchase a total of 16,650 shares at an exercise price of $22.13 per share (the closing price on January 23, 2026) and 8,400 restricted stock units to acquire common stock.
The grants were made pursuant to the company’s 2020 Inducement Plan, approved by the board in January 2020 under the NYSE inducement exception (Rule 303A.08).
Arcus (NYSE:RCUS) outlined 2026 priorities focused on advancing casdatifan (HIF-2a inhibitor) across late-line and first-line ccRCC, with at least three casdatifan data presentations planned in 2026 and a targeted Phase 3 1L study initiation by year-end 2026. The company expects to start a first oral MRGPRX2 antagonist clinical program in 2026 and advance a small-molecule TNF inhibitor into the clinic in late 2026/early 2027. Arcus reports approximately $1 billion cash and investments and expects funding through at least the second half of 2028, assuming a rapid wind down of select studies. Arcus will present at the J.P. Morgan Healthcare Conference on January 14, 2026.
Arcus Biosciences (NYSE:RCUS) announced that CEO Terry Rosen, Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
The presentation is scheduled for Wednesday, January 14, 2026 at 3:00 pm PT. A live webcast will be available via the company’s Investors & Media website and a replay will be posted after the event.
Arcus (NYSE:RCUS) will discontinue the Phase 3 STAR-221 study evaluating domvanalimab-based combination in advanced gastric and esophageal cancers after an Independent Data Monitoring Committee determined the trial met futility at a pre-specified interim overall survival analysis.
Arcus will stop STAR-221 and the Phase 2 EDGE-Gastric study, continue patient transition planning, and redirect R&D resources toward casdatifan (HIF-2a inhibitor) and an emerging inflammation & immunology small-molecule portfolio. Arcus reported casdatifan showed robust single-agent activity in >120 patients with late-line ccRCC and plans multiple casdatifan readouts and initiations across 2026, with potential Phase 3 registrational starts in late 2026. Arcus has ~$1B cash and investments, which it expects will fund operations into at least H2 2028.